Medtronic (BASE:MDTD) - Aktienkurs, Nachrichten und Analyse

Die Übersetzung dieser Seite ist experimentell und in Entwicklung. Wir freuen uns über Ihr !

MDTD Aktienübersicht

Develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide.

Über das Unternehmen

MDTD fundamental analysis
Snowflake Score
Valuation	1/6
Future Growth	1/6
Past Performance	2/6
Financial Health	5/6
Dividends	4/6

Belohnungen

Prognostiziertes Gewinnwachstum 11.15% pro Jahr

Risikoanalyse

Aktien sind hochgradig illiquide

Die Dividende von 3.13% ist durch die Erträge nicht gut gedeckt

Medtronic plc Wettbewerber

Boston Scientific

NYSE:BSX

US$111.6b

Stryker

NYSE:SYK

US$131.8b

Intuitive Surgical

NasdaqGS:ISRG

US$148.0b

Abbott Laboratories

NYSE:ABT

US$179.6b

Preisentwicklung & Leistung

Summary of all time highs, changes and price drops for Medtronic
Historical stock prices
Current Share Price	US$31.00
52 Week High	US$0
52 Week Low	US$0
Beta	0.72
1 Month Change	0%
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Aktuelle Nachrichten und Updates

Recent updates

Aktionärsrenditen

	MDTD	AR Medical Equipment	AR Markt
7D	0%	0%	0%
1Y	n/a	0%	0%

Rendite im Vergleich zur Industrie: Unzureichende Daten, um festzustellen, wie MDTD im Vergleich zur Branche AR Medical Equipment abschneidet.

Rendite vs. Markt: Unzureichende Daten, um festzustellen, wie MDTD im Vergleich zum AR Markt abgeschnitten hat.

Preisvolatilität

Is MDTD's price volatile compared to industry and market?
MDTD volatility
MDTD Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	0%
Market Average Movement	0%
10% most volatile stocks in AR Market	0%
10% least volatile stocks in AR Market	0%

Stabiler Aktienkurs: MDTD hatte in den letzten 3 Monaten keine nennenswerte Preisvolatilität.

Volatilität im Zeitverlauf: Unzureichende Daten, um die Volatilitätsveränderung von MDTD im vergangenen Jahr zu bestimmen.

Über das Unternehmen

Gegründet	Mitarbeiter	CEO	Website
1949	95,000	Geoff Martha	www.medtronic.com

Medtronic plc's Grundlagenzusammenfassung

Wie verhalten sich die Erträge und Einnahmen von Medtronic im Vergleich zum Marktanteil des Unternehmens?
MDTD grundlegende Statistiken
Marktanteil	US$115.93b
Gewinn(TTM)	US$3.76b
Umsatz(TTM)	US$31.23b

31.2x

Kurs-Gewinn-Verhältnis

3.8x

Kurs-Umsatz-Verhältnis

Ist MDTD zu teuer?

Siehe Fair Value und Bewertungsanalyse

Erträge & Einnahmen

Wichtige Rentabilitätsstatistiken aus dem letzten Ergebnisbericht (TTM)
MDTD Gewinn- und Verlustrechnung (TTM)
Einnahmen	US$31.23b
Kosten der Einnahmen	US$10.62b
Bruttogewinn	US$20.61b
Sonstige Ausgaben	US$16.85b
Umsatz	US$3.76b

Zuletzt gemeldete Gewinne

Apr 28, 2023

Datum des nächsten Gewinnberichts

Aug 22, 2023

Gewinn per Aktie (EPS)	2.82
Bruttomarge	65.98%
Nettogewinnspanne	12.03%
Schulden/Eigenkapital-Verhältnis	47.0%

Wie hat sich MDTD auf lange Sicht entwickelt?

Historische Performance und Vergleiche

Dividenden

3.1%

Aktuelle Dividendenrendite

96%

Ausschüttungsquote

MDTD Aktienübersicht

Belohnungen

Risikoanalyse

Medtronic plc Wettbewerber

NYSE:BSX

US$111.6b

NYSE:SYK

US$131.8b

NasdaqGS:ISRG

US$148.0b

NYSE:ABT

US$179.6b

Preisentwicklung & Leistung

Aktuelle Nachrichten und Updates

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Recent updates

Medtronic plc Announces Retirement of Rob Ten Hoedt as Executive Vice President and President, Global Regions, Effective as of June 28, 2024

Medtronic plc Increases Cash Dividend for the First Quarter of Fiscal Year 2025, Payable on July 12, 2024

Medtronic plc Announces its Investigational OmniaSecure Defibrillation Lead Met its Primary Safety and Effectiveness Endpoints, Existing Safety and Effectiveness Endpoints

Medtronic plc Receives FDA Approval for Inceptiv Closed-Loop Spinal Cord Stimulator

Medtronic plc Announces New Advancements in Artificial Intelligence for Endoscopic Care by Unveiling ColonPRO

Medtronic plc Announces SMART Trial One-Year Data Demonstrates Medtronic Evolut™ Tavr Platform as Optimal Treatment for Severe Aortic Stenosis in Patients with Small Annulus, Which Is Primarily Women

Medtronic plc Presents New Clinical and Real-World Data on the MiniMed™ 780G System from Around the World

Medtronic plc Approves Cash Dividend for the Fourth Quarter of Fiscal Year 2024, Payable on April 12, 2024

Medtronic plc to Report Q3, 2025 Results on Feb 18, 2025

Medtronic plc Announces FDA Approval of Its Percept™? RC Deep Brain Stimulation System

Medtronic Diabetes Announces World's First Approval for MiniMed™ 780G System with Simplera Sync™ Disposable, all-in-one sensor

Medtronic plc Announces FDA Approves the PulseSelect Pulsed Field Ablation System for the Treatment of Both Paroxysmal and Persistent Atrial Fibrillation

Medtronic Announces Cash Dividend for Third Quarter of Fiscal Year 2024, Payable on January 12, 2024

Medtronic plc Revises Earnings Guidance for the Fiscal Year 2024

Medtronic plc Announces Four-Year Results from the Evolut Low Risk Trial

Orchestra BioMed Holdings, Inc Grants FDA Approval of IDE to Initiate BACKBEAT Pivotal Study of BackBeat CNT™ for the Treatment of Hypertension in Pacemaker Patients

Medtronic Issues Statement on the FDA Circulatory Systems Devices Advisory Panel vote for the Symplicity Spyral Renal Denervation System

Medtronic plc Raises Earnings Guidance for 2024

Medtronic plc Approves Cash Dividend for the Second Quarter of Fiscal Year 2024, Payable on October 13, 2023

Medtronic plc Appoints Greg Lewis as New Director

Medtronic plc Presents New Data on MiniMed 780G System on Fixed Meal Dosing and Real-World Time in Range Across Wide Range of Users

Medtronic plc Appoints Ken Washington as Chief Technology and Innovation Officer

Medtronic plc Approves Cash Dividend for the First Quarter of Fiscal Year 2024, Payable on July 14, 2023

Medtronic plc Announces Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Medtronic Extravascular ICD Global Clinical Trial Results Reinforce Device Safety and Effectiveness

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Shockwave Medical Reportedly Picks Up Takeover Interest from Two Additional Suitors

Aktionärsrenditen

Preisvolatilität

Über das Unternehmen

Medtronic plc's Grundlagenzusammenfassung

31.2x

3.8x

Erträge &amp; Einnahmen

Dividenden

3.1%

96%

Erträge & Einnahmen